CN101821627A - 免疫原性链球菌蛋白质 - Google Patents
免疫原性链球菌蛋白质 Download PDFInfo
- Publication number
- CN101821627A CN101821627A CN200880110303A CN200880110303A CN101821627A CN 101821627 A CN101821627 A CN 101821627A CN 200880110303 A CN200880110303 A CN 200880110303A CN 200880110303 A CN200880110303 A CN 200880110303A CN 101821627 A CN101821627 A CN 101821627A
- Authority
- CN
- China
- Prior art keywords
- streptococcus
- albumen
- protein
- strains
- kinds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 365
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 306
- 230000002163 immunogen Effects 0.000 title claims abstract description 138
- 241000194054 Streptococcus uberis Species 0.000 claims abstract description 193
- 241000194017 Streptococcus Species 0.000 claims abstract description 176
- 229940115922 streptococcus uberis Drugs 0.000 claims abstract description 151
- 239000000203 mixture Substances 0.000 claims abstract description 134
- 238000000034 method Methods 0.000 claims abstract description 113
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 73
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 68
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 68
- 230000028993 immune response Effects 0.000 claims abstract description 65
- 239000013598 vector Substances 0.000 claims abstract description 59
- 229960005486 vaccine Drugs 0.000 claims abstract description 29
- 230000005847 immunogenicity Effects 0.000 claims description 176
- 239000008267 milk Substances 0.000 claims description 93
- 210000004080 milk Anatomy 0.000 claims description 92
- 235000013336 milk Nutrition 0.000 claims description 89
- 241001465754 Metazoa Species 0.000 claims description 84
- 210000002966 serum Anatomy 0.000 claims description 84
- 241001597008 Nomeidae Species 0.000 claims description 80
- 230000001580 bacterial effect Effects 0.000 claims description 62
- 208000004396 mastitis Diseases 0.000 claims description 48
- 210000000481 breast Anatomy 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 230000008521 reorganization Effects 0.000 claims description 36
- 230000014509 gene expression Effects 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 31
- 230000007924 bacterial virulence factor Effects 0.000 claims description 23
- 108091058545 Secretory proteins Proteins 0.000 claims description 22
- 102000040739 Secretory proteins Human genes 0.000 claims description 22
- 230000036039 immunity Effects 0.000 claims description 22
- 108010052285 Membrane Proteins Proteins 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 20
- 238000013016 damping Methods 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 19
- 230000009849 deactivation Effects 0.000 claims description 17
- 238000011534 incubation Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- 238000009396 hybridization Methods 0.000 claims description 9
- 239000001488 sodium phosphate Substances 0.000 claims description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 8
- 238000009007 Diagnostic Kit Methods 0.000 claims description 7
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 7
- 238000011156 evaluation Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000009465 prokaryotic expression Effects 0.000 claims description 5
- 230000007923 virulence factor Effects 0.000 claims description 5
- 239000000304 virulence factor Substances 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 102000018697 Membrane Proteins Human genes 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012749 thinning agent Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 238000013459 approach Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 269
- 210000004027 cell Anatomy 0.000 description 105
- 241000283690 Bos taurus Species 0.000 description 66
- 208000015181 infectious disease Diseases 0.000 description 39
- 239000000427 antigen Substances 0.000 description 35
- 241000894006 Bacteria Species 0.000 description 34
- 108091007433 antigens Proteins 0.000 description 34
- 102000036639 antigens Human genes 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 31
- 238000011081 inoculation Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 102400000368 Surface protein Human genes 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 235000015097 nutrients Nutrition 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000013600 plasmid vector Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 230000001276 controlling effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000002445 nipple Anatomy 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000002525 ultrasonication Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241000235058 Komagataella pastoris Species 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229940125575 vaccine candidate Drugs 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 5
- 241000588722 Escherichia Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 241000235649 Kluyveromyces Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000005075 mammary gland Anatomy 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 241000235342 Saccharomycetes Species 0.000 description 4
- 241000193985 Streptococcus agalactiae Species 0.000 description 4
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229940030998 streptococcus agalactiae Drugs 0.000 description 4
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000186146 Brevibacterium Species 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000194021 Streptococcus suis Species 0.000 description 3
- 241000235017 Zygosaccharomyces Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- ZGZLYKUHYXFIIO-UHFFFAOYSA-N 5-nitro-2h-tetrazole Chemical compound [O-][N+](=O)C=1N=NNN=1 ZGZLYKUHYXFIIO-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 208000031462 Bovine Mastitis Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 241000223233 Cutaneotrichosporon cutaneum Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 241001625930 Luria Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 2
- 241000499912 Trichoderma reesei Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- LQEATNFJCMVKAC-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-n-prop-2-enylprop-2-en-1-amine Chemical compound C1=CC=C2C(CCN(CC=C)CC=C)=CNC2=C1 LQEATNFJCMVKAC-UHFFFAOYSA-N 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 101150079312 pgk1 gene Proteins 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 108020001775 protein parts Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000009146 rhinoscleroma Diseases 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical class C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 241001619326 Cephalosporium Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 241000275449 Diplectrum formosum Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 208000006941 Laboratory Infection Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000011795 OF1 mouse Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 101100406395 Rhizobium leguminosarum bv. viciae ropA gene Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194046 Streptococcus intermedius Species 0.000 description 1
- 241000194055 Streptococcus parauberis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 238000013196 antibiotherapy Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 101150030367 cls gene Proteins 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000002478 diastatic effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001756 lactotroph Anatomy 0.000 description 1
- 230000001381 lactotroph Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 101150095421 tig gene Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56944—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113844.0 | 2007-08-06 | ||
| EP07113844A EP2023143A1 (en) | 2007-08-06 | 2007-08-06 | Immunogenic streptococcus proteins |
| PCT/NL2008/050537 WO2009020391A1 (en) | 2007-08-06 | 2008-08-05 | Immunogenic streptococcus proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101821627A true CN101821627A (zh) | 2010-09-01 |
Family
ID=38890252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880110303A Pending CN101821627A (zh) | 2007-08-06 | 2008-08-05 | 免疫原性链球菌蛋白质 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100297183A1 (https=) |
| EP (3) | EP2023143A1 (https=) |
| JP (2) | JP5462164B2 (https=) |
| KR (1) | KR20100063706A (https=) |
| CN (1) | CN101821627A (https=) |
| AR (1) | AR067830A1 (https=) |
| AU (1) | AU2008284491A1 (https=) |
| BR (1) | BRPI0815604A2 (https=) |
| CA (1) | CA2695721A1 (https=) |
| CL (1) | CL2008002320A1 (https=) |
| CO (1) | CO6270172A2 (https=) |
| DK (1) | DK2183597T3 (https=) |
| ES (1) | ES2432407T3 (https=) |
| MX (1) | MX2010001482A (https=) |
| RU (1) | RU2518315C2 (https=) |
| TW (1) | TW200911999A (https=) |
| UA (1) | UA103885C2 (https=) |
| WO (1) | WO2009020391A1 (https=) |
| ZA (1) | ZA201000806B (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102209555A (zh) * | 2008-10-06 | 2011-10-05 | 诺丁汉大学 | 含有分选酶锚定乳房链球菌表面蛋白的组合物 |
| CN107108756A (zh) * | 2014-12-22 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 细胞穿透性肽 |
| CN108135992A (zh) * | 2015-10-21 | 2018-06-08 | 米纳瓦克斯有限责任公司 | 免疫原性融合蛋白 |
| CN119780429A (zh) * | 2024-12-27 | 2025-04-08 | 华派生物技术(集团)股份有限公司 | 一种提高猪圆环病毒2型Cap蛋白抗原琼扩检测灵敏度的方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000005378A2 (en) | 1998-07-22 | 2000-02-03 | Id-Lelystad Instituut Voor Dierhouderij En Diergezondheid B.V. | Streptococcus suis vaccines and diagnostic tests |
| WO2002061070A2 (en) | 2001-02-02 | 2002-08-08 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Environmentally regulated genes, involved in the virulence of streptococcus suis |
| KR101943171B1 (ko) | 2013-09-19 | 2019-01-29 | 조에티스 서비시즈 엘엘씨 | 유성 아쥬반트 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| RU2685957C2 (ru) * | 2016-12-28 | 2019-04-23 | Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") | Химерный рекомбинантный белок, обладающий протективными свойствами в отношении Streptococcus pyogenes |
| CA3196872A1 (en) * | 2020-12-23 | 2022-06-30 | Chan Zuckerberg Biohub, Inc. | Bacteria-engineered to elicit antigen-specific t cells |
| CN112773891B (zh) * | 2021-02-01 | 2022-03-25 | 北部湾大学 | 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用 |
| CN119219752B (zh) * | 2024-09-12 | 2026-04-03 | 华中农业大学 | 一种猪链球菌抗原蛋白及其筛选方法及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000037105A2 (en) * | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283507A (en) | 1990-12-20 | 1994-02-01 | General Electric Company | Regenerative braking protection for an electrically-propelled traction vehicle |
| NL9100510A (nl) * | 1991-03-21 | 1992-10-16 | Centraal Diergeneeskundig Inst | Dna-sequenties die coderen voor kenmerken van virulentie van streptococcus suis en delen daarvan, daarvan afgeleide polypeptiden en antilichamen, alsmede toepassing daarvan bij de diagnose van en de bescherming tegen infectie met s. suis bij zoogdieren, waaronder de mens. |
| IT1251435B (it) | 1991-09-04 | 1995-05-09 | Sclavo Spa | Vettore genetico per la integrazione multipla stabile di sequenze di dna nel genoma dei lieviti kluyveromyces lactis e saccharomyces cerevisiae e plasmidi che lo contengono. |
| US5928900A (en) * | 1993-09-01 | 1999-07-27 | The Rockefeller University | Bacterial exported proteins and acellular vaccines based thereon |
| EP0804582A1 (en) * | 1994-05-16 | 1997-11-05 | The Uab Research Foundation | $i(STREPTOCOCCUS PNEUMONIAE) CAPSULAR POLYSACCHARIDE GENES AND FLANKING REGIONS |
| US5681570A (en) * | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
| EP0750042A1 (fr) * | 1995-06-20 | 1996-12-27 | Societe Des Produits Nestle S.A. | Bactéries lactiques produisant des exopolysaccharides |
| JP4108126B2 (ja) | 1996-04-26 | 2008-06-25 | リュクスウニヴェルシテート テ レイデン | Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン |
| US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| WO2000005378A2 (en) * | 1998-07-22 | 2000-02-03 | Id-Lelystad Instituut Voor Dierhouderij En Diergezondheid B.V. | Streptococcus suis vaccines and diagnostic tests |
| WO2000077178A1 (en) * | 1999-06-16 | 2000-12-21 | Boston Biomedical Research Institute | IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO |
| DE60136356D1 (de) * | 2000-06-12 | 2008-12-11 | Univ Saskatchewan | Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik |
| EP1205552A1 (en) * | 2000-11-09 | 2002-05-15 | ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. | Virulence of streptococci, involving ORFs from Streptococcus suis |
| WO2002061070A2 (en) * | 2001-02-02 | 2002-08-08 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Environmentally regulated genes, involved in the virulence of streptococcus suis |
| BR0316635A (pt) * | 2002-11-26 | 2005-10-11 | Univ Tennessee Res Foundation | Molécula de aderência de streptococcus uberis |
| EP1590368B1 (en) * | 2003-01-27 | 2014-02-26 | Københavns Universitet | Compounds useful in the diagnosis and treatment of pregnancy-associated malaria |
| EP2327720A1 (en) * | 2003-05-30 | 2011-06-01 | Intercell AG | Enterococcus antigens |
| WO2006048763A1 (en) * | 2004-11-05 | 2006-05-11 | Pharmacia & Upjohn Company Llc | Anti-bacterial vaccine compositions |
| HUE030269T2 (en) * | 2006-06-26 | 2017-04-28 | Macrogenics Inc | FC RIIB-specific antibodies and methods for their use |
-
2007
- 2007-08-06 EP EP07113844A patent/EP2023143A1/en not_active Withdrawn
-
2008
- 2008-08-05 RU RU2010107878/15A patent/RU2518315C2/ru not_active IP Right Cessation
- 2008-08-05 US US12/733,159 patent/US20100297183A1/en not_active Abandoned
- 2008-08-05 EP EP13170976.8A patent/EP2660604A3/en not_active Withdrawn
- 2008-08-05 JP JP2010519882A patent/JP5462164B2/ja not_active Expired - Fee Related
- 2008-08-05 DK DK08793829.6T patent/DK2183597T3/da active
- 2008-08-05 WO PCT/NL2008/050537 patent/WO2009020391A1/en not_active Ceased
- 2008-08-05 UA UAA201002376A patent/UA103885C2/ru unknown
- 2008-08-05 CN CN200880110303A patent/CN101821627A/zh active Pending
- 2008-08-05 CA CA2695721A patent/CA2695721A1/en not_active Abandoned
- 2008-08-05 AU AU2008284491A patent/AU2008284491A1/en not_active Abandoned
- 2008-08-05 MX MX2010001482A patent/MX2010001482A/es active IP Right Grant
- 2008-08-05 EP EP08793829.6A patent/EP2183597B1/en active Active
- 2008-08-05 ES ES08793829T patent/ES2432407T3/es active Active
- 2008-08-05 KR KR1020107004959A patent/KR20100063706A/ko not_active Ceased
- 2008-08-05 BR BRPI0815604-2A2A patent/BRPI0815604A2/pt not_active IP Right Cessation
- 2008-08-06 CL CL2008002320A patent/CL2008002320A1/es unknown
- 2008-08-06 TW TW097129912A patent/TW200911999A/zh unknown
- 2008-08-07 AR ARP080103446A patent/AR067830A1/es unknown
-
2010
- 2010-02-03 ZA ZA201000806A patent/ZA201000806B/xx unknown
- 2010-03-03 CO CO10025154A patent/CO6270172A2/es not_active Application Discontinuation
-
2014
- 2014-01-16 JP JP2014006098A patent/JP2014095721A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000037105A2 (en) * | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102209555A (zh) * | 2008-10-06 | 2011-10-05 | 诺丁汉大学 | 含有分选酶锚定乳房链球菌表面蛋白的组合物 |
| CN107108756A (zh) * | 2014-12-22 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 细胞穿透性肽 |
| CN108135992A (zh) * | 2015-10-21 | 2018-06-08 | 米纳瓦克斯有限责任公司 | 免疫原性融合蛋白 |
| US11325950B2 (en) | 2015-10-21 | 2022-05-10 | Minervax Aps | Immunogenic fusion protein |
| US12173033B2 (en) | 2015-10-21 | 2024-12-24 | Minervax Aps | Immunogenic fusion protein |
| CN119780429A (zh) * | 2024-12-27 | 2025-04-08 | 华派生物技术(集团)股份有限公司 | 一种提高猪圆环病毒2型Cap蛋白抗原琼扩检测灵敏度的方法 |
| CN119780429B (zh) * | 2024-12-27 | 2025-12-26 | 华派生物技术(集团)股份有限公司 | 一种提高猪圆环病毒2型Cap蛋白抗原琼扩检测灵敏度的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5462164B2 (ja) | 2014-04-02 |
| JP2014095721A (ja) | 2014-05-22 |
| CA2695721A1 (en) | 2009-02-12 |
| AU2008284491A1 (en) | 2009-02-12 |
| DK2183597T3 (da) | 2013-10-14 |
| BRPI0815604A2 (pt) | 2015-03-03 |
| AR067830A1 (es) | 2009-10-21 |
| EP2183597A1 (en) | 2010-05-12 |
| EP2183597B1 (en) | 2013-07-24 |
| CL2008002320A1 (es) | 2009-09-25 |
| MX2010001482A (es) | 2010-03-01 |
| UA103885C2 (en) | 2013-12-10 |
| KR20100063706A (ko) | 2010-06-11 |
| RU2010107878A (ru) | 2011-09-20 |
| US20100297183A1 (en) | 2010-11-25 |
| ZA201000806B (en) | 2010-10-27 |
| WO2009020391A1 (en) | 2009-02-12 |
| JP2010535500A (ja) | 2010-11-25 |
| EP2023143A1 (en) | 2009-02-11 |
| CO6270172A2 (es) | 2011-04-20 |
| EP2660604A3 (en) | 2014-02-12 |
| EP2660604A2 (en) | 2013-11-06 |
| TW200911999A (en) | 2009-03-16 |
| RU2518315C2 (ru) | 2014-06-10 |
| ES2432407T3 (es) | 2013-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101821627A (zh) | 免疫原性链球菌蛋白质 | |
| Nayak et al. | A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae | |
| KR100361562B1 (ko) | 프로테이나제k에대해내성을갖는네이쎄리아메닝기티디스의표면단백질 | |
| Hsueh et al. | Evaluation on a S treptococcus suis Vaccine Using Recombinant S ao‐L Protein Manufactured by Bioreactors as the Antigen in Pigs | |
| EP2046379A2 (en) | Immunogenic proteins of burkholderia pseudomallei and uses thereof | |
| Olvera et al. | Virulence-associated trimeric autotransporters of Haemophilus parasuis are antigenic proteins expressed in vivo | |
| Thomas et al. | A proteomic‐based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis | |
| JP4785014B2 (ja) | 蛋白質 | |
| US20100068214A1 (en) | Identification of Candidate Vaccine Antigens from Dichelobacter Nodosus | |
| SA98180918A (ar) | تسلسلات حامض نووي وحامض أميني تتعلق ببكتيريا h.pylori " وتركيبات لقاحية منها " | |
| Chiang et al. | Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model | |
| DE60124132T2 (de) | Immunisation von milchvieh mit gapc protein gegen streptococcus infektion | |
| EP0761819A1 (en) | Exopolysaccharides of burkholderia pseudomallei and burkholderia mallei | |
| Kowalski et al. | Antigenic characterization of Moraxella bovis, Moraxella bovoculi and Moraxella ovis strains with potential use in vaccines | |
| MX2010009516A (es) | Secuencias novedosas de brachyspira, composiciones inmunogenicas, metodos para la preparacion y usos de las mismas. | |
| JP2005523017A (ja) | Ｃａｎｄｉｄａａｌｂｉｃａｎｓ由来の細胞壁マンノプロテイン及び活性エピトープならびにこれらを認識する抗体 | |
| Kolberg et al. | Streptococcus pneumoniae heat shock protein 70 does not induce human antibody responses during infection | |
| Rose et al. | Acellular outer membrane vesicles of Brucella abortus strain 19 elicits both humoral and cell mediated immune response in mice. | |
| JP2001504335A (ja) | ストレプトコッカス・ユベリスのラクトフェリン結合タンパク質 | |
| Hübschle | In memory of Otto Hübschle | |
| CN100387718C (zh) | 抗蛋白酶k降解的脑膜炎奈瑟氏球菌表面蛋白 | |
| Jitsurong et al. | Searching for virulence Burkholderia pseudomallei genes by immunoscreening the λ ZAPII expressed genomic library | |
| Wiens | Structural and functional analysis of the 57 kDa protein produced by the fish pathogen, Renibacterium salmoninarum | |
| He | RETRACTED: Entamoeba histolytica: Cloning, expression and evaluation of the efficacy of a recombinant amebiasis cysteine proteinase gene (ACP1) antigen in minipig | |
| MRP | STREPTOCOCCUS PORCINUS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100901 |